Christoph Helwig

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · The Lancet Oncology · 2013 · 526 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss, Christopher R. Heery, Jeffrey Schlom et al. · Clinical Cancer Research · 2018 · 415 citations · Full text

Medicine, Oncology, Pharmacology +17

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Luis Paz‐Ares, Tae Min Kim, David Vicente et al. · Journal of Thoracic Oncology · 2020 · 221 citations · Full text

Medicine, Oncology, Pharmacology +16

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo

Thomas Dirschka, Peter Radny, R. Dominicus et al. · British Journal of Dermatology · 2011 · 181 citations

Medicine, Dermatology, Pharmacology +15

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

Changhoon Yoo, Do-Youn Oh, Hye Jin Choi et al. · Journal for ImmunoTherapy of Cancer · 2020 · 146 citations · Full text

Medicine, Oncology, Pharmacology +17